Quantum Genomics Quantum Genomics
  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
    • Strategy
  • Science
    • Pipeline
      • Firibastat – First-in-class – hypertension as monotherapy
      • Best-in-class – optimized treatment of hypertension and heart failure
      • Hypertension in combination
      • Firibastat – First-in-class – heart failure
    • The BAPAIs
    • Scientific Publications
  • Did you know that ?
    • Did you know that ?
    • High blood pressure
    • Heart failure
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Investors presentations
    • Equity research
    • Shareholder letter
    • General meetings
    • Shareholding
    • Governance
    • Financial calendar
    • Contacts
  • News & Media
    • Press releases
    • Press/Audio
    • Videos
  • Contact us
  • Français

News

2016/04/14 – 2015 annual report : acceleration of clinical trials, secured financing and internationalisation in progress

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…

14 April 2016
Quantum 2016-04-14T17:00:12+02:00
News

2016/03/24 – Quantum Genomics raises €8.6 Million in U.S. and Europe

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…

24 March 2016
Quantum 2016-03-24T07:30:21+01:00
News

2016/03/17 – Quantum Genomics raises €5.54m via private placement in the United States and launches a capital increase amounting to €2.94m

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…

17 March 2016
Quantum 2016-03-17T14:03:01+01:00
News

2016/02/03 – Quantum Genomics Expands U.S. Presence to Advance its Development Programs for Cardiovascular Diseases

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…

3 February 2016
Quantum 2016-02-03T18:30:19+01:00
News

2016/01/20 – Enhancement of Quantum Genomics’ intellectual property : new patent approved for the United States

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…

20 January 2016
Quantum 2016-01-20T18:00:59+01:00
News

2016/01/05 – Patient enrolment 100% completed for Phase IIa trial for high blood pressure

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…

5 January 2016
Quantum 2016-01-05T18:08:09+01:00

Posts navigation

Previous Page 1 2
Information
  • Blog
  • Home
  • Contact us
About

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Contact us

33 rue Marbeuf
75008 Paris

[email protected]
+33(0)1 85 34 77 70

Write us

Quick access
  • Strategy
  • Pipeline
  • Did you know that ?
  • Scientific Publications
Search

 

© 2019 Quantum Genomics - Legal notice - Website terms and conditions

  • Company
    • Management
    • Board of directors
    • Inventors
    • Scientific and clinical advisory board
    • Strategy
  • Science
    • Pipeline
      • Firibastat – First-in-class – hypertension as monotherapy
      • Best-in-class – optimized treatment of hypertension and heart failure
      • Hypertension in combination
      • Firibastat – First-in-class – heart failure
    • The BAPAIs
    • Scientific Publications
  • Did you know that ?
    • Did you know that ?
    • High blood pressure
    • Heart failure
  • Investors
    • Press releases
    • Financial documents
      • Annual information
      • Semi-annual information
      • Other regulated informations
    • Investors presentations
    • Equity research
    • Shareholder letter
    • General meetings
    • Shareholding
    • Governance
    • Financial calendar
    • Contacts
  • News & Media
    • Press releases
    • Press/Audio
    • Videos
  • Contact us
  • Français
  • Blog
  • Home
  • Contact us